Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: Time to address gaps in care

S. L. Sawyer, T. Hartley, D. A. Dyment, C. L. Beaulieu, J. Schwartzentruber, A. Smith, H. M. Bedford, G. Bernard, F. P. Bernier, B. Brais, D. E. Bulman, J. Warman Chardon, D. Chitayat, J. Deladoëy, B. A. Fernandez, P. Frosk, M. T. Geraghty, B. Gerull, W. Gibson, R. M. GowG. E. Graham, J. S. Green, E. Heon, G. Horvath, A. M. Innes, N. Jabado, R. H. Kim, R. K. Koenekoop, A. Khan, O. J. Lehmann, R. Mendoza-Londono, J. L. Michaud, S. M. Nikkel, L. S. Penney, C. Polychronakos, J. Richer, G. A. Rouleau, M. E. Samuels, V. M. Siu, O. Suchowersky, M. A. Tarnopolsky, G. Yoon, F. R. Zahir, J. Majewski, K. M. Boycott, FORGE Canada Consortium, Care4Rare Canada Consortium

Research output: Contribution to journalReview article

142 Citations (Scopus)

Abstract

An accurate diagnosis is an integral component of patient care for children with rare genetic disease. Recent advances in sequencing, in particular whole-exome sequencing (WES), are identifying the genetic basis of disease for 25-40% of patients. The diagnostic rate is probably influenced by when in the diagnostic process WES is used. The Finding Of Rare Disease GEnes (FORGE) Canada project was a nation-wide effort to identify mutations for childhood-onset disorders using WES. Most children enrolled in the FORGE project were toward the end of the diagnostic odyssey. The two primary outcomes of FORGE were novel gene discovery and the identification of mutations in genes known to cause disease. In the latter instance, WES identified mutations in known disease genes for 105 of 362 families studied (29%), thereby informing the impact of WES in the setting of the diagnostic odyssey. Our analysis of this dataset showed that these known disease genes were not identified prior to WES enrollment for two key reasons: genetic heterogeneity associated with a clinical diagnosis and atypical presentation of known, clinically recognized diseases. What is becoming increasingly clear is that WES will be paradigm altering for patients and families with rare genetic diseases.

Original languageEnglish
Pages (from-to)275-284
Number of pages10
JournalClinical Genetics
Volume89
Issue number3
DOIs
Publication statusPublished - 1 Mar 2016
Externally publishedYes

Fingerprint

Exome
Rare Diseases
Inborn Genetic Diseases
Genes
Mutation
Genetic Heterogeneity
Genetic Association Studies
Canada
Patient Care

Keywords

  • Clinical exome
  • FORGE Canada Consortium
  • Rare diseases
  • Whole-exome sequencing

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Sawyer, S. L., Hartley, T., Dyment, D. A., Beaulieu, C. L., Schwartzentruber, J., Smith, A., ... Care4Rare Canada Consortium (2016). Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: Time to address gaps in care. Clinical Genetics, 89(3), 275-284. https://doi.org/10.1111/cge.12654

Utility of whole-exome sequencing for those near the end of the diagnostic odyssey : Time to address gaps in care. / Sawyer, S. L.; Hartley, T.; Dyment, D. A.; Beaulieu, C. L.; Schwartzentruber, J.; Smith, A.; Bedford, H. M.; Bernard, G.; Bernier, F. P.; Brais, B.; Bulman, D. E.; Warman Chardon, J.; Chitayat, D.; Deladoëy, J.; Fernandez, B. A.; Frosk, P.; Geraghty, M. T.; Gerull, B.; Gibson, W.; Gow, R. M.; Graham, G. E.; Green, J. S.; Heon, E.; Horvath, G.; Innes, A. M.; Jabado, N.; Kim, R. H.; Koenekoop, R. K.; Khan, A.; Lehmann, O. J.; Mendoza-Londono, R.; Michaud, J. L.; Nikkel, S. M.; Penney, L. S.; Polychronakos, C.; Richer, J.; Rouleau, G. A.; Samuels, M. E.; Siu, V. M.; Suchowersky, O.; Tarnopolsky, M. A.; Yoon, G.; Zahir, F. R.; Majewski, J.; Boycott, K. M.; FORGE Canada Consortium; Care4Rare Canada Consortium.

In: Clinical Genetics, Vol. 89, No. 3, 01.03.2016, p. 275-284.

Research output: Contribution to journalReview article

Sawyer, SL, Hartley, T, Dyment, DA, Beaulieu, CL, Schwartzentruber, J, Smith, A, Bedford, HM, Bernard, G, Bernier, FP, Brais, B, Bulman, DE, Warman Chardon, J, Chitayat, D, Deladoëy, J, Fernandez, BA, Frosk, P, Geraghty, MT, Gerull, B, Gibson, W, Gow, RM, Graham, GE, Green, JS, Heon, E, Horvath, G, Innes, AM, Jabado, N, Kim, RH, Koenekoop, RK, Khan, A, Lehmann, OJ, Mendoza-Londono, R, Michaud, JL, Nikkel, SM, Penney, LS, Polychronakos, C, Richer, J, Rouleau, GA, Samuels, ME, Siu, VM, Suchowersky, O, Tarnopolsky, MA, Yoon, G, Zahir, FR, Majewski, J, Boycott, KM, FORGE Canada Consortium & Care4Rare Canada Consortium 2016, 'Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: Time to address gaps in care', Clinical Genetics, vol. 89, no. 3, pp. 275-284. https://doi.org/10.1111/cge.12654
Sawyer SL, Hartley T, Dyment DA, Beaulieu CL, Schwartzentruber J, Smith A et al. Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: Time to address gaps in care. Clinical Genetics. 2016 Mar 1;89(3):275-284. https://doi.org/10.1111/cge.12654
Sawyer, S. L. ; Hartley, T. ; Dyment, D. A. ; Beaulieu, C. L. ; Schwartzentruber, J. ; Smith, A. ; Bedford, H. M. ; Bernard, G. ; Bernier, F. P. ; Brais, B. ; Bulman, D. E. ; Warman Chardon, J. ; Chitayat, D. ; Deladoëy, J. ; Fernandez, B. A. ; Frosk, P. ; Geraghty, M. T. ; Gerull, B. ; Gibson, W. ; Gow, R. M. ; Graham, G. E. ; Green, J. S. ; Heon, E. ; Horvath, G. ; Innes, A. M. ; Jabado, N. ; Kim, R. H. ; Koenekoop, R. K. ; Khan, A. ; Lehmann, O. J. ; Mendoza-Londono, R. ; Michaud, J. L. ; Nikkel, S. M. ; Penney, L. S. ; Polychronakos, C. ; Richer, J. ; Rouleau, G. A. ; Samuels, M. E. ; Siu, V. M. ; Suchowersky, O. ; Tarnopolsky, M. A. ; Yoon, G. ; Zahir, F. R. ; Majewski, J. ; Boycott, K. M. ; FORGE Canada Consortium ; Care4Rare Canada Consortium. / Utility of whole-exome sequencing for those near the end of the diagnostic odyssey : Time to address gaps in care. In: Clinical Genetics. 2016 ; Vol. 89, No. 3. pp. 275-284.
@article{016b038cc2664a67af07078a0c1d49bf,
title = "Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: Time to address gaps in care",
abstract = "An accurate diagnosis is an integral component of patient care for children with rare genetic disease. Recent advances in sequencing, in particular whole-exome sequencing (WES), are identifying the genetic basis of disease for 25-40{\%} of patients. The diagnostic rate is probably influenced by when in the diagnostic process WES is used. The Finding Of Rare Disease GEnes (FORGE) Canada project was a nation-wide effort to identify mutations for childhood-onset disorders using WES. Most children enrolled in the FORGE project were toward the end of the diagnostic odyssey. The two primary outcomes of FORGE were novel gene discovery and the identification of mutations in genes known to cause disease. In the latter instance, WES identified mutations in known disease genes for 105 of 362 families studied (29{\%}), thereby informing the impact of WES in the setting of the diagnostic odyssey. Our analysis of this dataset showed that these known disease genes were not identified prior to WES enrollment for two key reasons: genetic heterogeneity associated with a clinical diagnosis and atypical presentation of known, clinically recognized diseases. What is becoming increasingly clear is that WES will be paradigm altering for patients and families with rare genetic diseases.",
keywords = "Clinical exome, FORGE Canada Consortium, Rare diseases, Whole-exome sequencing",
author = "Sawyer, {S. L.} and T. Hartley and Dyment, {D. A.} and Beaulieu, {C. L.} and J. Schwartzentruber and A. Smith and Bedford, {H. M.} and G. Bernard and Bernier, {F. P.} and B. Brais and Bulman, {D. E.} and {Warman Chardon}, J. and D. Chitayat and J. Delado{\"e}y and Fernandez, {B. A.} and P. Frosk and Geraghty, {M. T.} and B. Gerull and W. Gibson and Gow, {R. M.} and Graham, {G. E.} and Green, {J. S.} and E. Heon and G. Horvath and Innes, {A. M.} and N. Jabado and Kim, {R. H.} and Koenekoop, {R. K.} and A. Khan and Lehmann, {O. J.} and R. Mendoza-Londono and Michaud, {J. L.} and Nikkel, {S. M.} and Penney, {L. S.} and C. Polychronakos and J. Richer and Rouleau, {G. A.} and Samuels, {M. E.} and Siu, {V. M.} and O. Suchowersky and Tarnopolsky, {M. A.} and G. Yoon and Zahir, {F. R.} and J. Majewski and Boycott, {K. M.} and {FORGE Canada Consortium} and {Care4Rare Canada Consortium}",
year = "2016",
month = "3",
day = "1",
doi = "10.1111/cge.12654",
language = "English",
volume = "89",
pages = "275--284",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Utility of whole-exome sequencing for those near the end of the diagnostic odyssey

T2 - Time to address gaps in care

AU - Sawyer, S. L.

AU - Hartley, T.

AU - Dyment, D. A.

AU - Beaulieu, C. L.

AU - Schwartzentruber, J.

AU - Smith, A.

AU - Bedford, H. M.

AU - Bernard, G.

AU - Bernier, F. P.

AU - Brais, B.

AU - Bulman, D. E.

AU - Warman Chardon, J.

AU - Chitayat, D.

AU - Deladoëy, J.

AU - Fernandez, B. A.

AU - Frosk, P.

AU - Geraghty, M. T.

AU - Gerull, B.

AU - Gibson, W.

AU - Gow, R. M.

AU - Graham, G. E.

AU - Green, J. S.

AU - Heon, E.

AU - Horvath, G.

AU - Innes, A. M.

AU - Jabado, N.

AU - Kim, R. H.

AU - Koenekoop, R. K.

AU - Khan, A.

AU - Lehmann, O. J.

AU - Mendoza-Londono, R.

AU - Michaud, J. L.

AU - Nikkel, S. M.

AU - Penney, L. S.

AU - Polychronakos, C.

AU - Richer, J.

AU - Rouleau, G. A.

AU - Samuels, M. E.

AU - Siu, V. M.

AU - Suchowersky, O.

AU - Tarnopolsky, M. A.

AU - Yoon, G.

AU - Zahir, F. R.

AU - Majewski, J.

AU - Boycott, K. M.

AU - FORGE Canada Consortium

AU - Care4Rare Canada Consortium

PY - 2016/3/1

Y1 - 2016/3/1

N2 - An accurate diagnosis is an integral component of patient care for children with rare genetic disease. Recent advances in sequencing, in particular whole-exome sequencing (WES), are identifying the genetic basis of disease for 25-40% of patients. The diagnostic rate is probably influenced by when in the diagnostic process WES is used. The Finding Of Rare Disease GEnes (FORGE) Canada project was a nation-wide effort to identify mutations for childhood-onset disorders using WES. Most children enrolled in the FORGE project were toward the end of the diagnostic odyssey. The two primary outcomes of FORGE were novel gene discovery and the identification of mutations in genes known to cause disease. In the latter instance, WES identified mutations in known disease genes for 105 of 362 families studied (29%), thereby informing the impact of WES in the setting of the diagnostic odyssey. Our analysis of this dataset showed that these known disease genes were not identified prior to WES enrollment for two key reasons: genetic heterogeneity associated with a clinical diagnosis and atypical presentation of known, clinically recognized diseases. What is becoming increasingly clear is that WES will be paradigm altering for patients and families with rare genetic diseases.

AB - An accurate diagnosis is an integral component of patient care for children with rare genetic disease. Recent advances in sequencing, in particular whole-exome sequencing (WES), are identifying the genetic basis of disease for 25-40% of patients. The diagnostic rate is probably influenced by when in the diagnostic process WES is used. The Finding Of Rare Disease GEnes (FORGE) Canada project was a nation-wide effort to identify mutations for childhood-onset disorders using WES. Most children enrolled in the FORGE project were toward the end of the diagnostic odyssey. The two primary outcomes of FORGE were novel gene discovery and the identification of mutations in genes known to cause disease. In the latter instance, WES identified mutations in known disease genes for 105 of 362 families studied (29%), thereby informing the impact of WES in the setting of the diagnostic odyssey. Our analysis of this dataset showed that these known disease genes were not identified prior to WES enrollment for two key reasons: genetic heterogeneity associated with a clinical diagnosis and atypical presentation of known, clinically recognized diseases. What is becoming increasingly clear is that WES will be paradigm altering for patients and families with rare genetic diseases.

KW - Clinical exome

KW - FORGE Canada Consortium

KW - Rare diseases

KW - Whole-exome sequencing

UR - http://www.scopus.com/inward/record.url?scp=84958105945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958105945&partnerID=8YFLogxK

U2 - 10.1111/cge.12654

DO - 10.1111/cge.12654

M3 - Review article

C2 - 26283276

AN - SCOPUS:84958105945

VL - 89

SP - 275

EP - 284

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 3

ER -